Targeting vascular risk in patients with metabolic syndrome but without diabetes.
about
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitisThe prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balanceFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewDo we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?Cardiovascular benefits of bariatric surgery in morbidly obese patients.Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentRationale for multiple risk intervention: the need to move from theory to practice.Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.Do statins reduce events in patients with metabolic syndrome?Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatment.Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome statusImplementation of guidelines for the management of arterial hypertension. The impulsion studyCardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed populationAtorvastatin: safety and tolerability.Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis.Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.Normalization of metabolic syndrome using fenofibrate, metformin or their combination.Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.Prevalence, characteristics, and in-hospital outcomes of metabolic syndrome among acute coronary syndrome patients from Oman.Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?
P2860
Q24201595-5A146351-8423-4462-8DB5-24A1E1B56AE4Q27003277-3B1A227D-3078-4C13-AFA6-8D3027D9D567Q28220294-D4F23EF8-23C3-4439-B854-AEE8B8A2F534Q28222549-238ABF7A-EF25-4DF3-B27A-885E684AEDD8Q33829180-8F8689CD-F04A-4A4E-9415-D93F212900E2Q34068746-B7AB20F8-62A7-492C-8362-36FFC6C060F8Q35029623-7307069D-A4EC-4FCF-8B56-E22C16B6EBA6Q36596889-D0335292-A6B3-4626-808E-80826ACED532Q36653658-9978B328-DF66-4F9F-AD76-D9F40F7FEBA4Q36773310-50C527F4-1A31-4054-983F-026D7ED1FBAAQ37119260-F5CF5362-8CE8-47EF-AAA2-3B9C208354CEQ37163499-2F3243B0-5E80-4256-AC7F-8BB5510BA908Q37183071-E69EC373-0C07-4BA4-AB8D-0CF15DB83AD6Q37239716-3BF051D2-A18D-4237-8C80-BFC1636103CCQ37454427-0789BB52-6EA2-43F8-80E5-087B1FE2AB6DQ37765562-ADE1E339-ABA1-44F8-A4AB-7B1268891977Q38853504-F904EFBC-92F4-4D5A-92A7-B9BDA990216AQ38867031-24100EF6-D106-4E77-ADD7-7B24210083B0Q46959415-5B466CA6-AB2B-49AB-B08F-E7AEEE547ADBQ51366717-1091791F-756B-4429-94B8-83F47B81B902Q51461225-980B4E29-692D-4A27-9152-913B3C076FF8Q58149661-A9682592-74C8-4469-A321-DE1135F7C029
P2860
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
@en
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
@nl
type
label
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
@en
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
@nl
prefLabel
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
@en
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
@nl
P2093
P1433
P1476
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
@en
P2093
Anna I Kakafika
Asterios Karagiannis
Athanasia Peletidou
Athanasios A Papageorgiou
Drosia Kleta
Konstantinos Tziomalos
Moses Elisaf
Triandafillos P Didangelos
P304
P356
10.1016/J.METABOL.2005.03.010
P577
2005-08-01T00:00:00Z